{"company":{"id":3783071,"name":"Prelude Therapeutics","domain":"preludetx.com","url":"https://alion.io/company/world-3783071"},"section":"news","answer":"Prelude Therapeutics: 23 headlines on record, 5 headlines in the last 90 days. Its story counts 9 milestones.","figures":[{"label":"Headlines","value":"23"},{"label":"In 90 days","value":"5"},{"label":"Milestones","value":"9"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":23},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":9}],"news":[{"date":"2026-10-07","kind":"Blog","title":"Precision Degrader Antibody Conjugates (DACs): An Emerging Modality in Targeted Therapeutics","url":"https://preludetx.com/precision-degrader-antibody-conjugates-dacs-an-emerging-modality-in-targeted-therapeutics/"},{"date":"2026-09-23","kind":"News","title":"Prelude Therapeutics stock falls 9.9 percent despite FDA progress","source":"Prelude Therapeutics stock falls 9.9 percent despite FDA progress","url":"https://ad-hoc-news.de/boerse/news/nebenwerte/prelude-therapeutics-stock-falls-9-9-percent-despite-fda-progress/70168790"},{"date":"2026-09-20","kind":"News","title":"Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial","source":"Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial","url":"https://ad-hoc-news.de/boerse/news/nebenwerte/prelude-therapeutics-stock-gains-as-fda-clears-new-breast-cancer-drug/70139836"},{"date":"2026-09-10","kind":"News","title":"Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/prelude-therapeutics-receives-fda-clearance-110100304.html"},{"date":"2026-08-22","kind":"News","title":"Prelude Therapeutics Cuts Quarterly Net Loss 55% As R&D Spending Falls 38%","source":"Pulse 2.0","url":"https://pulse2.com/prelude-therapeutics-cuts-quarterly-net-loss-55-as-rd-spending-falls-38/"},{"date":"2026-07-22","kind":"Blog","title":"Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia","url":"https://preludetx.com/precision-degrader-antibody-conjugates-pdacs-with-a-smarca2-4-dual-payload-as-targeted-therapeutics-for-acute-myeloid-leukemia/"},{"date":"2026-04-20","kind":"Blog","title":"First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile","url":"https://preludetx.com/first-in-class-potent-and-selective-oral-kat6a-degrader-development-candidate-prt13722-drives-complete-tumor-regressions-as-a-monotherapy-with-an-improved-preclinical-hematological-safety-profile/"},{"date":"2026-04-20","kind":"News","title":"Prelude Therapeutics prices $90M equity offering","source":"seekingalpha.com","url":"https://seekingalpha.com/news/4576489-prelude-therapeutics-prices-90m-equity-offering"},{"date":"2026-04-15","kind":"Blog","title":"Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Precision Degrader-Antibody Conjugates (DACs)","url":"https://preludetx.com/beyond-conventional-payloads-unlocking-new-therapeutic-landscapes-with-precision-degrader-antibody-conjugates-dacs/"},{"date":"2026-03-15","kind":"Blog","title":"Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads","url":"https://preludetx.com/discovery-of-precision-degrader-antibody-conjugates-pdacs-employing-novel-smarca2-4-degrader-payloads/"},{"date":"2025-12-06","kind":"Blog","title":"Discovery of First-in-Class Calreticulin-targeted Degrader Antibody Conjugates Delivering a CDK9 Degrader Payload for the Treatment of CALR-mutated MPNs","url":"https://preludetx.com/discovery-of-first-in-class-calreticulin-targeted-degrader-antibody-conjugates-delivering-a-cdk9-degrader-payload-for-the-treatment-of-calr-mutated-mpns/"},{"date":"2025-12-06","kind":"Blog","title":"Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms","url":"https://preludetx.com/discovery-and-preclinical-characterization-of-orally-bioavailable-jak2v617f-mutant-selective-jh2-inhibitors-with-disease-modification-potential-in-myeloproliferative-neoplasms/"},{"date":"2025-11-08","kind":"News","title":"Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline Realignment","source":"YahooFinance","url":"https://finance.yahoo.com/news/prelude-therapeutics-prld-valuation-snapshot-051802260.html"},{"date":"2025-11-04","kind":"News","title":"Prelude Therapeutics pauses clinical development of SMARCA2 degrader program","source":"seekingalpha.com","url":"https://seekingalpha.com/news/4514236-prelude-therapeutics-pauses-clinical-development-of-smarca2-degrader-program"},{"date":"2025-11-04","kind":"Blog","title":"Sri Sahasranaman, Ph.D.","url":"https://preludetx.com/sri-sahasranaman-ph-d/"},{"date":"2025-11-04","kind":"News","title":"Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges","source":"SeekingAlpha","url":"https://seekingalpha.com/article/4837058-prelude-therapeutics-a-subtle-shift-in-pipeline-underscores-funding-challenges"},{"date":"2025-08-11","kind":"News","title":"Can Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?","source":"YahooFinance","url":"https://finance.yahoo.com/news/prelude-therapeutics-nasdaq-prld-afford-113223467.html"},{"date":"2025-06-18","kind":"Blog","title":"A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed / Refractory Lymphoid Malignancies: Updated Analysis","url":"https://preludetx.com/a-phase-1-study-of-prt2527-a-selective-cdk9-inhibitor-as-monotherapy-and-in-combination-with-zanubrutinib-in-relapsed-refractory-lymphoid-malignancies-updated-analysis/"},{"date":"2025-06-18","kind":"Blog","title":"Discovery of First-in-Class Precision Antibody Drug Conjugates Targeting Mutant Calreticulin For the Treatment of Myeloproliferative Neoplasms","url":"https://preludetx.com/discovery-of-first-in-class-precision-antibody-drug-conjugates-targeting-mutant-calreticulin-for-the-treatment-of-myeloproliferative-neoplasms/"},{"date":"2025-05-31","kind":"Blog","title":"A Phase 2 Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and a SMARCA4 Mutation","url":"https://preludetx.com/a-phase-2-safety-and-efficacy-study-of-prt3789-in-combination-with-pembrolizumab-in-patients-with-advanced-or-metastatic-solid-tumors-and-a-smarca4-mutation/"},{"date":"2025-04-24","kind":"News","title":"Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting","source":"Nasdaq","url":"https://nasdaq.com/articles/prelude-therapeutics-presents-preclinical-data-first-class-smarca2-and-selective-kat6a"},{"date":"2024-12-22","kind":"News","title":"Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics","source":"YahooFinance","url":"https://finance.yahoo.com/news/krishna-vaddi-bought-4-9-120005287.html"},{"date":"2024-10-25","kind":"News","title":"Prelude Therapeutics price target lowered to $1 from $3 at Barclays","source":"Nasdaq","url":"https://nasdaq.com/articles/prelude-therapeutics-price-target-lowered-1-3-barclays"}],"story":[{"title":"Certified Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degra… · YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/prelude-therapeutics-receives-fda-clearance-110100304.html"},{"title":"New executive Brian Piper, Executive Officer · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866020000001/"},{"title":"Raised a round Venture round $50M · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866020000001/"},{"title":"New executive David Mauro, Executive Officer · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866019000001/"},{"title":"Raised a round Venture round $30M · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866019000001/"},{"title":"New executive Juan Luengo, Executive Officer · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866017000001/"},{"title":"Raised a round Venture round $30M · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866017000001/"},{"title":"Raised a round Venture round $5M · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1678660/000167866016000001/"},{"title":"Founded"}],"as_of":"2026-11-17","cite":"Prelude Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/world-3783071/news","html_url":"https://alion.io/company/world-3783071/news","json_url":"https://alion.io/company/world-3783071/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T20:40:56Z"}}